Indication
Local short-term anesthesia of the cornea and conjunctiva: during removal of foreign cornea and conjunctiva particles; conducting ophthalmic tonometry, gonioscopy and other diagnostic examinations; preparation for subconjunctival and retrobulbane injections.
Composition of the substance
active substance:oxybuprocamine hydrochloride;
1 ml of solution contains oxybuprocamine hydrochloride 4 mg;
excipients: boric acid, chlorhexidine diacetate, water for injection.
Medicinal form
Eye drops, solution.
Pharmacological properties
Pharmacodynamics.
The active ingredient of the drug oxybuprocamine hydrochloride is a synthetic local anesthetic belonging to the group of esters of para-aminobenzoic acid. This is a potent superficial anesthetic that shows a rapidly increasing effect and makes a short-term local anesthetic effect (10-20 minutes). Occurring in therapeutic doses to sensitive nerve endings, oxibuprocaine leads to a reversible blockage of the onset and transfer of impulses and, thus, causes temporary anesthesia at the site of digestion. It does not affect the pupil width of the eye and the ability to accomodate. After the local anesthetic effect, the pupil’s sensitivity returns to the initial state. In vitro oxybuprocin has a weak antibacterial effect.
Pharmacokinetics.
After immersion in the conjunctival sac, oxybuprocamine is absorbed into the circulatory system in a small amount. In the blood, oxibuprocaine is immediately metabolized by the esterase of the plasma (by breaking the etheric link) to the formation of inactive metabolites. The main metabolite is 3-butoxy-4-aminobenzoic acid, 80% of which is excreted by the kidneys in the form of a compound with glucuronic acid.
Producer
«UNIMED PHARMA Ltd».
Location of the manufacturer and the address of the place of its operation
Orieskova 11, 821 05 Bratislava, Slovak Republic.